Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin
- PMID: 19221403
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin
Abstract
Background: Sitagliptin is a highly selective dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Sitagliptin is primarily excreted by renal elimination as unchanged drug, with only a small percentage (approximately 16%) undergoing hepatic metabolism.
Objectives: The primary purpose of this study was to evaluate the influence of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Methods: In an open-label study, a single 100-mg oral dose of sitagliptin was administered to 10 male or female patients with moderate hepatic insufficiency (Child-Pugh's scores ranged from 7 to 9) and 10 healthy control subjects matched to each patient for race, gender, age (+/- 5 yrs) and body mass index (BMI kg/m2 +/- 5%). After administration of each dose, blood and urine samples were collected to assess sitagliptin pharmacokinetics.
Results: The mean AUC(0-infinity) and Cmax for sitagliptin were numerically, but not significantly (p>0.050), higher in patients with moderate hepatic insufficiency compared with healthy matched control subjects by 21% and 13%, respectively. These slight differences were also not considered to be clinically meaningful. Moderate hepatic insufficiency had no statistically significant effect on the Tmax, apparent terminal t(1/2), fraction of the oral dose excreted into urine (f(e,0-infinity)) and renal clearance (ClR) (p>0.100) of sitagliptin. Sitagliptin was generally well tolerated by both patients and subjects; all adverse experiences were transient and rated as mild in intensity.
Conclusions: Moderate hepatic insufficiency has no clinically meaningful effect on the pharmacokinetics of sitagliptin.
Similar articles
-
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.Clin Ther. 2006 Jan;28(1):55-72. doi: 10.1016/j.clinthera.2006.01.015. Clin Ther. 2006. PMID: 16490580 Clinical Trial.
-
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.Biopharm Drug Dispos. 2007 Sep;28(6):315-22. doi: 10.1002/bdd.560. Biopharm Drug Dispos. 2007. PMID: 17575559 Clinical Trial.
-
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.Biopharm Drug Dispos. 2007 Sep;28(6):307-13. doi: 10.1002/bdd.559. Biopharm Drug Dispos. 2007. PMID: 17571284 Clinical Trial.
-
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43. doi: 10.1345/aph.1G665. Ann Pharmacother. 2006. PMID: 16868220 Review.
-
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):745-58. doi: 10.1517/17425255.2012.686603. Epub 2012 May 16. Expert Opin Drug Metab Toxicol. 2012. PMID: 22587686 Review.
Cited by
-
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.1007/BF03261927. Clin Pharmacokinet. 2012. PMID: 22686547 Review.
-
Inpatient treatment of type 2 diabetes.Dtsch Arztebl Int. 2012 Jun;109(26):466-74. doi: 10.3238/arztebl.2012.0466. Epub 2012 Jun 29. Dtsch Arztebl Int. 2012. PMID: 22833757 Free PMC article. Review.
-
Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Can J Gastroenterol. 2012 Jun;26(6):353-7. doi: 10.1155/2012/725468. Can J Gastroenterol. 2012. PMID: 22720278 Free PMC article. Review.
-
Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis.Indian J Endocrinol Metab. 2018 Jul-Aug;22(4):552-559. doi: 10.4103/ijem.IJEM_79_18. Indian J Endocrinol Metab. 2018. PMID: 30148106 Free PMC article. Review.
-
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Drugs. 2014 Feb;74(2):223-42. doi: 10.1007/s40265-013-0169-1. Drugs. 2014. PMID: 24407560 Review.